Senti Biosciences (SNTI)
NASDAQ:SNTI
Want to see SNTI full AI Analyst Report?
Top Page
Senti Biosciences
(NASDAQ:SNTI)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.00
▼(-9.09% Downside)
Action:Reiterated
Date:05/15/26
The score is primarily constrained by weak financial fundamentals (minimal revenue, large losses, ongoing cash burn, and thin equity cushion). Technicals are modestly supportive in the near term but not yet long-term bullish. Corporate updates add some upside from SENTI-202 progress, partially offset by financing and execution risk; valuation support is limited due to continued losses.
Positive Factors
Regulatory clarity for SENTI-202
FDA feedback supporting a single-arm pivotal design plus RMAT and Orphan Drug designations materially reduces regulatory uncertainty for SENTI-202. This clarifies a potential registration path for an off-the-shelf CAR‑NK therapy, improving approval probability and long-term partner interest.
Negative Factors
Minimal revenue, large recurring losses
With effectively no product revenue ($22K) and a TTM net loss near $51.5M, Senti lacks operating cash generation. Persistent negative margins mean continued dependence on external financing and partnership milestones, raising dilution risk and making long‑term viability contingent on clinical success or recurring capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clarity for SENTI-202
FDA feedback supporting a single-arm pivotal design plus RMAT and Orphan Drug designations materially reduces regulatory uncertainty for SENTI-202. This clarifies a potential registration path for an off-the-shelf CAR‑NK therapy, improving approval probability and long-term partner interest.
Read all positive factors
Senti Biosciences (SNTI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.46M
Dividend YieldN/A
Average Volume (3M)260.00K
Price to Earnings (P/E)―
Beta (1Y)2.13
Revenue GrowthN/A
EPS Growth73.56%
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.92
Shares Outstanding31,144,754
10 Day Avg. Volume505,690
30 Day Avg. Volume260,000
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue1.59K
Enterprise Value/Gross Profit-14.88
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$12.00Price Target Upside990.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$50.00K
Senti Biosciences Business Overview & Revenue Model
Company Description
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to re...
How the Company Makes Money
Senti Biosciences does not have a marketed product and is not known to generate recurring product sales; as a clinical-stage biotech, it primarily funds operations through external financing and collaboration-related payments rather than commercia...
Senti Biosciences Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.00K | 22.00K | 0.00 | 1.98M | 3.29M | 2.29M |
| Gross Profit | -2.35M | -3.62M | 0.00 | 1.98M | 3.29M | 2.29M |
| EBITDA | -46.84M | -60.09M | -54.88M | -61.34M | -58.16M | -37.44M |
| Net Income | -51.55M | -61.44M | -52.79M | -71.06M | -58.21M | -55.32M |
Balance Sheet | ||||||
| Total Assets | 38.24M | 51.22M | 97.84M | 119.48M | 180.79M | 96.70M |
| Cash, Cash Equivalents and Short-Term Investments | 8.94M | 16.42M | 48.28M | 35.93M | 98.56M | 56.03M |
| Total Debt | 19.14M | 28.89M | 33.64M | 37.67M | 37.09M | 22.73M |
| Total Liabilities | 35.68M | 45.63M | 72.19M | 52.57M | 53.53M | 36.33M |
| Stockholders Equity | 2.56M | 5.59M | 25.65M | 66.91M | 127.26M | 60.38M |
Cash Flow | ||||||
| Free Cash Flow | -37.07M | -43.64M | -41.42M | -64.43M | -76.27M | -40.18M |
| Operating Cash Flow | -36.88M | -43.44M | -41.40M | -52.40M | -34.90M | -34.63M |
| Investing Cash Flow | -58.00K | -184.00K | 34.00K | 30.08M | -81.96M | -5.54M |
| Financing Cash Flow | 12.06M | 11.76M | 53.73M | 779.00K | 118.55M | 68.44M |
Senti Biosciences Technical Analysis
Negative
1.10
Price Trends
0.95
Negative
0.98
Negative
1.33
Negative
Market Momentum
<0.01
Positive
46.64
Neutral
39.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNTI, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 1.00, above the 50-day MA of 0.95, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.64 is Neutral, neither overbought nor oversold. The STOCH value of 39.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNTI.
Senti Biosciences Risk Analysis
Senti Biosciences disclosed 102 risk factors in its most recent earnings report. Senti Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Senti Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $173.82M | -1.37 | 77.87% | ― | 6.33% | -102.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $31.46M | -1.49 | -503.79% | ― | ― | 73.56% | |
49 Neutral | $37.53M | -1.10 | -64.17% | ― | -100.00% | 94.65% | |
48 Neutral | $27.76M | -1.05 | -70.57% | ― | -100.00% | 21.30% | |
42 Neutral | $36.03M | -0.97 | -198.48% | ― | -0.46% | 96.28% |
* Healthcare Sector Average
SNTI
Senti Biosciences
0.94
-2.30
-70.99%
PSTV
Plus Therapeutics
5.84
-2.54
-30.27%
KPTI
Karyopharm Therapeutics
7.14
2.01
39.32%
TVRD
Tvardi Therapeutics
4.00
-22.20
-84.73%
BRNS
Barinthus Biotherapeutics
0.64
-0.21
-24.94%
Senti Biosciences Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Senti Biosciences Advances SENTI-202 With New FDA Support
Positive
May 14, 2026
On May 14, 2026, Senti Biosciences reported first-quarter 2026 results and highlighted progress on SENTI-202, including positive FDA feedback that supports a single-arm, multi-center pivotal trial design in relapsed/refractory acute myeloid leukem...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Senti Biosciences Secures Convertible Note Financing with Celadon
Positive
May 1, 2026
On April 27, 2026, Senti Biosciences Holdings, Inc. and its subsidiaries entered into a securities purchase agreement with an investor affiliated with major shareholder Celadon Partners SPV 24 for a private placement of up to $40 million in senior...
Business Operations and Strategy
Senti Biosciences Plans Tax-Free Holding Company Reorganization
Neutral
Apr 1, 2026
On April 1, 2026, Senti Biosciences announced plans for a holding company reorganization, expected to take effect by April 16, 2026, through a tax-free merger into a new Delaware subsidiary structure that will result in Senti Biosciences Holdings ...
Business Operations and StrategyRegulatory Filings and Compliance
Senti Biosciences Amends Lease, Restructures GeneFab Sublease
Negative
Mar 19, 2026
On March 17, 2026, Senti Biosciences, Inc. amended its main Alameda, California lease to cut its occupied space in half to about 45,955 square feet effective September 1, 2025, reducing base rent and its share of operating expenses and taxes, whil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.